Materialise NV Q4 2025 Earnings Call Highlights
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 19 2026
0mins
Should l Buy MTLS?
Source: seekingalpha
- Dual Listing Advantage: Materialise NV completed its dual listing on Euronext Brussels, which, while not raising capital, broadens its European investor base and enhances operational flexibility, potentially paving the way for future ADS or share buyback initiatives.
- Share Buyback Implementation: The company announced a share buyback program of up to EUR 30 million, having already repurchased 187,500 shares for nearly USD 1 million, demonstrating a commitment to shareholder value and market confidence.
- Medical Business Growth: The Medical segment treated over 17,000 patients in 2025, surpassing a cumulative total of 700,000 patients, with expectations for continued double-digit growth, solidifying its position as a key growth driver for the company.
- Strong Financial Performance: In Q4 2025, revenue grew by 6.8% year-on-year to EUR 70.2 million, with a gross profit margin of 58.1% and adjusted EBIT of EUR 4 million, reflecting ongoing improvements in cost control and profitability.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy MTLS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on MTLS
About MTLS
Materialise NV is a Belgium-based company that is engaged in the software industry. The Company is a provider of software and three-dimensional (3D) printing services that incorporates 3D printing experience into a wide range of software solutions and 3D printing services. It transforms businesses with three elements of align: quality, reliability, and repeatability through which it forms the backbone of the 3D printing industry. The solutions are built 3D printing applications in several industries, including healthcare, automotive, aerospace, art and design, and consumer goods. It also operates in the domestic market and worldwide, including Colombia, Brazil, Australia, Malaysia, China, Japan, Austria, Poland, Germany, and France, among others.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Materialise to Release Q1 2026 Financial Results on May 7
- Earnings Release Schedule: Materialise NV will announce its financial results for Q1 2026 on May 7 at 1:00 a.m. ET, reflecting the company's commitment to transparency and timely information disclosure.
- Management Conference Call: Senior management will hold a conference call on the same day at 8:30 a.m. ET to discuss the Q1 financial results, aiming to enhance investor understanding and confidence in the company's performance.
- Webcast Availability: The conference call will be accessible via a live audio webcast on the company's website, ensuring global investors can receive real-time information and fostering better engagement between the company and its investors.
- Industry Leadership: As a global leader in 3D-printed medical devices and software, Materialise's innovation and technological expertise will lay a strong foundation for its future financial performance, attracting increased investor interest.
See More
Materialise to Release Q1 2026 Financial Results
- Earnings Release Schedule: Materialise NV will announce its financial results for Q1 2026 on May 7, 2026, at 1:00 a.m. ET, providing critical financial data to assess the company's performance.
- Management Conference Call: On the same day, senior management will hold a conference call at 8:30 a.m. ET to discuss the Q1 financial results, aiming to provide investors and analysts with in-depth performance analysis and future outlook.
- Webcast Access: Investors can access the audio webcast of the conference call through the company’s website, ensuring transparent information dissemination, while the call will be archived for later review, enhancing information accessibility.
- Company Background: Materialise boasts over 30 years of 3D printing experience, offering a range of software solutions and services aimed at driving innovation across healthcare, automotive, aerospace, and other industries, showcasing its leadership in the global 3D printing sector.
See More
Materialise Transfers RapidFit Business to Management Team
- Increased Business Independence: Materialise's decision to transfer the RapidFit business to its management team allows it to operate as an independent company, enhancing market flexibility and customer focus, with the transaction expected to close around April 30, 2026.
- Core Business Focus: This move aligns with Materialise's growth strategy by concentrating investments and resources on the most promising business lines while enabling RapidFit to leverage its core strengths to drive global growth.
- Technological Advantage Utilization: RapidFit specializes in delivering custom 3D-printed jigs and quality control solutions for the automotive and manufacturing sectors, utilizing advanced additive manufacturing technologies to improve production efficiency, reduce lead times, and support quality assurance processes.
- Stable Customer Impact: The transaction is not expected to affect existing customer orders or ongoing projects, ensuring that RapidFit can maintain continuity in customer service after becoming independent.
See More
Materialise NV Q4 2025 Earnings Call Highlights
- Dual Listing Advantage: Materialise NV completed its dual listing on Euronext Brussels, which, while not raising capital, broadens its European investor base and enhances operational flexibility, potentially paving the way for future ADS or share buyback initiatives.
- Share Buyback Implementation: The company announced a share buyback program of up to EUR 30 million, having already repurchased 187,500 shares for nearly USD 1 million, demonstrating a commitment to shareholder value and market confidence.
- Medical Business Growth: The Medical segment treated over 17,000 patients in 2025, surpassing a cumulative total of 700,000 patients, with expectations for continued double-digit growth, solidifying its position as a key growth driver for the company.
- Strong Financial Performance: In Q4 2025, revenue grew by 6.8% year-on-year to EUR 70.2 million, with a gross profit margin of 58.1% and adjusted EBIT of EUR 4 million, reflecting ongoing improvements in cost control and profitability.
See More
Materialise Q4 Earnings Beat Expectations with Strong Revenue Growth
- Earnings Highlights: Materialise reported a GAAP EPS of $0.12 for Q4 2025, with revenue of $82.44 million exceeding expectations by $0.42 million and reflecting a year-over-year growth of 6.8%, indicating robust market performance.
- Adjusted EBITDA Growth: The adjusted EBITDA for Q4 increased significantly to 9,524 kEUR from 4,306 kEUR in 2024, showcasing a marked improvement in profitability and reflecting enhanced operational efficiency.
- Free Cash Flow Performance: The free cash flow for Q4 2025 was 4,511 kEUR, down from 6,218 kEUR in 2024, yet still demonstrating solid cash flow management that supports future investments.
- Future Outlook: The company anticipates full-year revenues for 2026 to grow to a range of 273,000 to 283,000 kEUR, with continued investments in its Medical and Software segments while maintaining cost discipline, projecting adjusted EBIT of 10,000 to 12,000 kEUR, indicating strong growth potential.
See More
Materialise NV Reports Strong Q4 and Full Year 2025 Financial Results
- Significant Revenue Growth: Total revenue for Q4 2025 reached €70.164 million, a 6.8% increase year-over-year, demonstrating strong performance in the medical device sector, particularly with a 16.3% rise in medical segment revenue to €37.016 million, further solidifying market leadership.
- Improved Profitability: Adjusted EBITDA for Q4 2025 surged to €9.524 million from €4.306 million in the same period of 2024, reflecting successful cost control and operational efficiency, which is expected to enhance investor confidence.
- Robust Cash Flow: As of December 31, 2025, the company reported €133.918 million in cash and cash equivalents, with a net cash position improving to €70.805 million, indicating strong financial health and the ability to continue investing in R&D and market expansion.
- Optimistic Future Outlook: The company anticipates full-year revenues for 2026 to range between €273,000 and €283,000, with continued strong growth in the medical segment and a transition to a cloud-based subscription model in the software segment, showcasing proactive positioning for future market opportunities.
See More
Materialise to Release Q1 2026 Financial Results on May 7
- Earnings Release Schedule: Materialise NV will announce its financial results for Q1 2026 on May 7 at 1:00 a.m. ET, reflecting the company's commitment to transparency and timely information disclosure.
- Management Conference Call: Senior management will hold a conference call on the same day at 8:30 a.m. ET to discuss the Q1 financial results, aiming to enhance investor understanding and confidence in the company's performance.
- Webcast Availability: The conference call will be accessible via a live audio webcast on the company's website, ensuring global investors can receive real-time information and fostering better engagement between the company and its investors.
- Industry Leadership: As a global leader in 3D-printed medical devices and software, Materialise's innovation and technological expertise will lay a strong foundation for its future financial performance, attracting increased investor interest.
See More
Materialise to Release Q1 2026 Financial Results
- Earnings Release Schedule: Materialise NV will announce its financial results for Q1 2026 on May 7, 2026, at 1:00 a.m. ET, providing critical financial data to assess the company's performance.
- Management Conference Call: On the same day, senior management will hold a conference call at 8:30 a.m. ET to discuss the Q1 financial results, aiming to provide investors and analysts with in-depth performance analysis and future outlook.
- Webcast Access: Investors can access the audio webcast of the conference call through the company’s website, ensuring transparent information dissemination, while the call will be archived for later review, enhancing information accessibility.
- Company Background: Materialise boasts over 30 years of 3D printing experience, offering a range of software solutions and services aimed at driving innovation across healthcare, automotive, aerospace, and other industries, showcasing its leadership in the global 3D printing sector.
See More
Materialise Transfers RapidFit Business to Management Team
- Increased Business Independence: Materialise's decision to transfer the RapidFit business to its management team allows it to operate as an independent company, enhancing market flexibility and customer focus, with the transaction expected to close around April 30, 2026.
- Core Business Focus: This move aligns with Materialise's growth strategy by concentrating investments and resources on the most promising business lines while enabling RapidFit to leverage its core strengths to drive global growth.
- Technological Advantage Utilization: RapidFit specializes in delivering custom 3D-printed jigs and quality control solutions for the automotive and manufacturing sectors, utilizing advanced additive manufacturing technologies to improve production efficiency, reduce lead times, and support quality assurance processes.
- Stable Customer Impact: The transaction is not expected to affect existing customer orders or ongoing projects, ensuring that RapidFit can maintain continuity in customer service after becoming independent.
See More
Materialise NV Q4 2025 Earnings Call Highlights
- Dual Listing Advantage: Materialise NV completed its dual listing on Euronext Brussels, which, while not raising capital, broadens its European investor base and enhances operational flexibility, potentially paving the way for future ADS or share buyback initiatives.
- Share Buyback Implementation: The company announced a share buyback program of up to EUR 30 million, having already repurchased 187,500 shares for nearly USD 1 million, demonstrating a commitment to shareholder value and market confidence.
- Medical Business Growth: The Medical segment treated over 17,000 patients in 2025, surpassing a cumulative total of 700,000 patients, with expectations for continued double-digit growth, solidifying its position as a key growth driver for the company.
- Strong Financial Performance: In Q4 2025, revenue grew by 6.8% year-on-year to EUR 70.2 million, with a gross profit margin of 58.1% and adjusted EBIT of EUR 4 million, reflecting ongoing improvements in cost control and profitability.
See More
Materialise Q4 Earnings Beat Expectations with Strong Revenue Growth
- Earnings Highlights: Materialise reported a GAAP EPS of $0.12 for Q4 2025, with revenue of $82.44 million exceeding expectations by $0.42 million and reflecting a year-over-year growth of 6.8%, indicating robust market performance.
- Adjusted EBITDA Growth: The adjusted EBITDA for Q4 increased significantly to 9,524 kEUR from 4,306 kEUR in 2024, showcasing a marked improvement in profitability and reflecting enhanced operational efficiency.
- Free Cash Flow Performance: The free cash flow for Q4 2025 was 4,511 kEUR, down from 6,218 kEUR in 2024, yet still demonstrating solid cash flow management that supports future investments.
- Future Outlook: The company anticipates full-year revenues for 2026 to grow to a range of 273,000 to 283,000 kEUR, with continued investments in its Medical and Software segments while maintaining cost discipline, projecting adjusted EBIT of 10,000 to 12,000 kEUR, indicating strong growth potential.
See More
Materialise NV Reports Strong Q4 and Full Year 2025 Financial Results
- Significant Revenue Growth: Total revenue for Q4 2025 reached €70.164 million, a 6.8% increase year-over-year, demonstrating strong performance in the medical device sector, particularly with a 16.3% rise in medical segment revenue to €37.016 million, further solidifying market leadership.
- Improved Profitability: Adjusted EBITDA for Q4 2025 surged to €9.524 million from €4.306 million in the same period of 2024, reflecting successful cost control and operational efficiency, which is expected to enhance investor confidence.
- Robust Cash Flow: As of December 31, 2025, the company reported €133.918 million in cash and cash equivalents, with a net cash position improving to €70.805 million, indicating strong financial health and the ability to continue investing in R&D and market expansion.
- Optimistic Future Outlook: The company anticipates full-year revenues for 2026 to range between €273,000 and €283,000, with continued strong growth in the medical segment and a transition to a cloud-based subscription model in the software segment, showcasing proactive positioning for future market opportunities.
See More
